• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Huntington’s Disease Treatment Companies

    ID: MRFR/Pharma/5466-HCR
    90 Pages
    Rahul Gotadki
    September 2025

    Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by the progressive deterioration of cognitive and motor functions. As researchers strive to unravel the complexities of this genetic condition, several companies have emerged as leaders in developing groundbreaking treatments and therapies.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Huntington’s Disease Treatment Market

    Huntington

     


    Latest Huntington’s Disease Treatment Companies Updates:


    Roche partners with NeuExcell Therapeutics for gene therapy research: This collaboration combines expertise to develop potential gene therapy solutions for HD patients.


    Spark Therapeutics and F. Hoffmann-La Roche collaborate on genetic therapy: This partnership aims to advance development of gene therapy candidate SPARC131 for HD treatment.


    Huntington's Disease Society of America (HDSA): Provides information and resources for patients, families, and healthcare professionals affected by HD.


    Genetic Alliance: Advocacy organization representing patients and families affected by genetic conditions, including HD.


    List of Huntington’s Disease Treatment  Key companies in the market:



    • AmpliPhi Biosciences Corp

    • Ceregene Inc

    • Lundbeck

    • Prana Biotechnology Limited

    • Teva Pharmaceutical Industries Ltd

    • Cortex Pharmaceuticals Inc

    • Vertex Pharmaceuticals Incorporated

    • Auspex Pharmaceuticals

    • SOM Biotech

    • GlaxoSmithKline

    •  Siena Biotech